A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer

Official title

A Multicenter, Open-label Phase Ib/II Clinical Trial of SHR-A2102 Injection in Combination With Adebrelimab Injection, With or Without Other Anti-tumor Therapies, in Subjects With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Overview

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102/SHR-9839(sc) with Adebrelimab with or without other Antitumor Therapy in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. To explore the reasonable dosage of SHR-A2102/SHR-9839（sc） for Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Interventions

• Drug SHR-A2102
  Administration by intravenous infusion
• Drug Adebrelimab
  Administration by intravenous infusion
• Drug Cetuximab
  Administration by intravenous infusion
• Drug SHR-9839(sc)
  Administration by Subcutaneous injection
• Drug Carboplatin / Cisplatin
  Administration by intravenous infusion

Primary outcome measures

• RP2D [Time frame: through phase IB completion, an average of 5 years]
• Incidence and severity of AE(DLT) [Time frame: from Day1 to 90 days after last dose]
• ORR [Time frame: 5 years after the last subject was enrolled in the group]

Secondary outcome measures (4)

• DCR [Time frame: 5 years after the last subject was enrolled in the group]
• DOR [Time frame: 5 years after the last subject was enrolled in the group]
• PFS(Investigator evaluation) [Time frame: 5 years after the last subject was enrolled in the group]
• OS(Investigator evaluation) [Time frame: 5 years after the last subject was enrolled in the group]

Eligibility criteria

Inclusion criteria

• Have the ability to give informed consent, have signed informed and able to comply with the treatment plan to visit the tests and other procedural requirements.
• Subject with advanced or distant metastatic squamous cell carcinoma of the head and neck confirmed by histology or cytology.
• At least one measurable lesion according to RECIST v1.1 criteria.
• The ECOG score is 0 or 1.
• Expected survival ≥12 weeks.
• Male subjects whose partners are women of childbearing age and female subjects who are fertile are required to use highly effective contraceptive methods.

Exclusion criteria

\-

1\. Subjects will not be screened if they meet any of the following conditions:

• Primary tumor located in the nasopharynx, salivary glands, sinuses, skin, or squamous cell carcinoma of unknown primary origin;
• Locally advanced patients who are candidates for curative surgery or local therapy and have the intention to undergo such treatment;

2\. Known hypersensitivity to the investigational drug or any of its excipients, or a history of severe allergic reactions to other monoclonal antibodies.

3\. Prior treatments or medications before the first dose of the study drug:

• Use of any investigational drug within 4 weeks before the first dose;
• Concurrent enrollment in another clinical trial, unless it is an observational (non-interventional) study or follow-up in an interventional study; 4. Active autoimmune disease or a history of autoimmune disorders. 5. Residual toxicity from prior anticancer therapy not resolved to ≤Grade 1 (CTCAE v5.0) (except for non-safety risks, such as alopecia) or not meeting the inclusion/exclusion criteria.

6\. Uncontrolled or symptomatic active CNS metastases. 7. Symptomatic visceral metastases with imminent life-threatening complications .

8\. Severe bone damage caused by tumor bone metastasis, including severe bone pain that is poorly controlled; pathological fractures in important areas that occurred within 6 months before the first medication or are expected to occur very soon; and spinal cord compression.

9\. Known or suspected interstitial lung disease (ILD) or severe pulmonary conditions.

10\. Other active malignancies within 3 years before study entry. 11. Have a history of immunodeficiency, including a positive HIV test result, or suffer from other acquired or congenital immune deficiency diseases, or have a history of organ transplantation and allogeneic bone marrow transplantation.

12\. Clinically significant cardiovascular disease. 13. Active or chronic infections of clinical significance. 14. Pregnancy or lactation. 15. Other factors that, in the investigator's judgment, may lead to premature study discontinuation.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Non-randomized

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

China · 2 centers

• Chongqing University Cancer Hospital — Chongqing
• West China Hospital of Sichuan University — Chengdu

Identifiers

NCT: NCT07059221 · SHR-A2102-211

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗